{
  "abstract": "In 2023, the Italian Medicines Agency approved the reimbursement of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis (PrEP). A single generic formulation became available. Infectious disease specialists were allowed to prescribe a maximum of three boxes (90 days of coverage). In October 2024, the sole authorised manufacturer announced production issues.",
  "authors": [
    {
      "affiliations": [
        "Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Roberto Rossotti"
    },
    {
      "affiliations": [
        "Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Maria Cristina Moioli"
    },
    {
      "affiliations": [
        "Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Chiara Baiguera"
    },
    {
      "affiliations": [
        "Hospital Pharmacy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Martina Milani"
    },
    {
      "affiliations": [
        "Hospital Pharmacy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Cosimo De Giorgio"
    },
    {
      "affiliations": [
        "Hospital Pharmacy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"
      ],
      "name": "Loretta Cervi"
    },
    {
      "affiliations": [
        "Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy",
        "Università degli Studi di Milano-Bicocca, Milano, Italy"
      ],
      "name": "Massimo Puoti"
    }
  ],
  "title": "Ongoing shortage of generic emtricitabine/tenofovir disoproxil fumarate undermines HIV prevention efforts among PrEP users in Italy",
  "uid": "a78b48fd-55b3-5b5e-b7fd-c5110866a26f"
}